Primary Aldosteronism Associated with Multiple Adrenocortical Micronodules in a Patient with Renal Cell Carcinoma.
Journal
Case reports in endocrinology
ISSN: 2090-6501
Titre abrégé: Case Rep Endocrinol
Pays: United States
ID NLM: 101576457
Informations de publication
Date de publication:
2020
2020
Historique:
received:
09
10
2019
accepted:
16
01
2020
entrez:
12
3
2020
pubmed:
12
3
2020
medline:
12
3
2020
Statut:
epublish
Résumé
A 47-year-old woman with a history of diabetes mellitus (DM) and obesity was admitted to our hospital for glucose control. She was detected to have hypertension (HT) and diagnosed with primary aldosteronism (PA) based on the high level of aldosterone to renin ratio and the results of the upright furosemide-loading test according to the criteria of the Japanese Society of Hypertension (JSH) guidelines. Computed tomography revealed left renal tumor and adrenocortical adenoma. She underwent left nephrectomy and adrenalectomy. The pathological findings were clear-cell renal cell carcinoma (RCC) and nonfunctional adrenocortical adenoma. Her nonneoplastic adrenal tissue histologically revealed CYP11B2-positive multiple adrenocortical micronodules (MNs) and concomitant paradoxical hyperplasia of the zona glomerulosa. Therefore, MNs were thought to be responsible for PA in this patient. After surgery, HT was improved, and the result of upright furosemide-loading test after 12 months of surgery did not fulfill the criteria of PA according to the JSH guidelines. However, the adrenocorticotrophic hormone stimulation test was positive; considering the possibility of slight aldosterone overproduction from the right adrenal gland, the administration of spironolactone was started. Herein, we report a rare case of RCC in conjunction with PA histologically associated with MNs.
Identifiants
pubmed: 32158565
doi: 10.1155/2020/2808101
pmc: PMC7060454
doi:
Types de publication
Case Reports
Langues
eng
Pagination
2808101Informations de copyright
Copyright © 2020 Kazuhito Oba et al.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Free Radic Biol Med. 2013 Jan;54:17-25
pubmed: 23104102
Wiad Lek. 2011;64(2):104-8
pubmed: 22026274
J Clin Endocrinol Metab. 2016 May;101(5):1889-916
pubmed: 26934393
AJR Am J Roentgenol. 1981 Jan;136(1):81-4
pubmed: 6779583
Metabolism. 2002 Mar;51(3):350-5
pubmed: 11887172
J Clin Endocrinol Metab. 2016 Apr;101(4):1656-63
pubmed: 26844843
Free Radic Biol Med. 2011 Dec 1;51(11):1996-2006
pubmed: 21946068
Mol Cell Endocrinol. 2014 Mar 5;383(1-2):111-7
pubmed: 24325867
Endocr J. 2005 Aug;52(4):435-9
pubmed: 16127211
Am J Surg Pathol. 2002 Dec;26(12):1612-9
pubmed: 12459628
Urologiia. 2008 Mar-Apr;(2):16-22
pubmed: 18574876
Rinsho Byori. 2006 Nov;54(11):1157-63
pubmed: 17240838
Int J Exp Pathol. 2014 Aug;95(4):244-50
pubmed: 24802662
Virchows Arch A Pathol Anat Histopathol. 1988;413(4):313-8
pubmed: 3140475
Am J Surg Pathol. 1989 Mar;13(3):202-6
pubmed: 2919718
Hypertens Res. 2014 Apr;37(4):253-390
pubmed: 24705419
J Hypertens. 2014 Oct;32(10):2022-9; discussion 2029
pubmed: 24979305
Am J Hypertens. 2010 Dec;23(12):1253-60
pubmed: 20706195
Mol Carcinog. 2011 Feb;50(2):123-35
pubmed: 21229609
J UOEH. 2005 Dec 1;27(4):315-23
pubmed: 16358925
Nihon Hinyokika Gakkai Zasshi. 2000 Jun;91(6):565-9
pubmed: 10897583
J Clin Endocrinol Metab. 2017 Apr 1;102(4):1182-1192
pubmed: 28388725
Urol Oncol. 2015 Nov;33(11):476-85
pubmed: 26296264
N Engl J Med. 1998 Dec 17;339(25):1828-34
pubmed: 9854120
J Clin Endocrinol Metab. 2013 Apr;98(4):1567-74
pubmed: 23443813
Pathol Int. 2017 Apr;67(4):214-221
pubmed: 28261922
Semin Reprod Med. 2012 Oct;30(5):374-81
pubmed: 23044873
Am J Hypertens. 2008 Nov;21(11):1269-72
pubmed: 18772856
J Clin Endocrinol Metab. 2010 May;95(5):2296-305
pubmed: 20200334
J Clin Endocrinol Metab. 2016 Jan;101(1):6-9
pubmed: 26580238
Proc Natl Acad Sci U S A. 2015 Aug 18;112(33):E4591-9
pubmed: 26240369